-
Oct 6, 2025, 9:30 pm290 ptsTop
Slashdot
AstraZeneca has licensed Algen Biotechnologies' AI-powered gene-editing platform, AlgenBrain, to develop immune-related therapies in a deal worth up to $555 million. Reuters reports: AstraZeneca will get exclusive rights to develop and sell approved therapies, if any, that target immune system-related disorders…
Trending Today on Tech News Tube
Tech News Tube is a real time news feed of the latest technology news headlines.
Follow all of the top tech sites in one place, on the web or your mobile device.
Follow all of the top tech sites in one place, on the web or your mobile device.
